| Age (years), median (range) |
63 (44–80) |
63 (34–88) |
0.977 |
| Sex, percentage male/female |
59/41 |
63/37 |
0.561 |
| Binet stage B/C, n (%) |
54 (86) |
119 (72) |
0.088 |
| CIRS score, median (range) |
2 (0–8) |
3 (0–9) |
0.916 |
| Beta2-microglobulin, median (range) |
2.0 (1.3–6.1) |
2.1 (1.0–16.5) |
0.374 |
| High ZAP70 expression, n (%) |
34 (58) |
104 (65) |
0.350 |
| High CD38 expression, n (%) |
25 (49) |
75 (51) |
0.871 |
| Unmutated IGHV genes, n (%) |
37 (71) |
115 (83) |
0.069 |
| 11q deletion by FISH, n (%) |
9 (17) |
38 (24) |
0.343 |
| 17p deletion by FISH, n (%) |
2 (4) |
22 (14) |
0.074 |
|
TP53 mutation, n (%) |
3 (6) |
16 (13) |
0.288 |
|
NOTCH1 mutation, n (%) |
8 (16) |
23 (16) |
1.0 |
|
SF3B1 mutation, n (%) |
8 (15) |
22 (16) |
1.0 |
| Date of therapy initiation, median (range) |
September 2004 (January 2000–August 2014) |
January 2008 (January 2000–June 2014) |
|
